Notice of Intent to Sole Source – CARDINAL HEALTH 414, LLC– radiopharmaceuticals

This notice announces a sole‑source procurement by the NIH Clinical Center for up to $900,000 worth of FDA‑approved radiopharmaceuticals needed for patient care in the Nuclear Medicine Division. The contract will be awarded to CARDINAL HEALTH 414, LLC without a competitive solicitation, leveraging FAR Part 13 simplified acquisition procedures. The vendor is uniquely qualified due to a 25‑year relationship with the Clinical Center and its patented tungsten delivery system that reduces radiation exposure and staff injury risk. • Scope: Purchase of radiopharmaceuticals covering gamma, positron, beta, and alpha emissions, delivered via a specialized tungsten system. • Value: Not‑to‑Exceed $900,000 for a single purchase order. • Procurement method: Sole‑source award under FAR Part 13, exempt from competition requirements; no RFQ will be issued. • Key dates: Posted 13 Oct 2026; comments accepted through 19 Oct 2026 12 PM EST. • Point of contact: Ryssa Nix, Contract Specialist ([email protected]).